6533b86efe1ef96bd12cbc57
RESEARCH PRODUCT
G-CSF dosing schedule to prevent eribulin-induced neutropenia: Can modelling and simulation help?
Pierre FumoleauMaria Inês PereiraNicolas IsambertIsabelle DesmoulinsAntonin SchmittBruno Coudertsubject
OncologyCancer Researchmedicine.medical_specialtySchedulebusiness.industryNeutropeniamedicine.diseaseMetastatic breast cancerchemistry.chemical_compoundOncologychemistryInternal medicinemedicineMicrotubule InhibitorDosingIntensive care medicinebusinessEribulindescription
e20673 Background: Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer and should be administered on day 1 and 8 of each 21-day cycle. Neutrope...
year | journal | country | edition | language |
---|---|---|---|---|
2015-05-20 | Journal of Clinical Oncology |